Skip to Content

Pharmaceutical Industry News

FDA Warns Consumers Who Purchase Diazepam Online of Potentially Serious Counterfeiting Issue

Posted 3 weeks ago in Pharma Industry News

July 6, 2015 -- The FDA is warning consumers who purchase Diazepam, an anti-anxiety medication, on the internet of the potential risk that this drug may be counterfeit. The World Health Organization (WHO) has reported 700 adverse events from patients in Central Africa taking mislabeled Diazepam that was actually the anti-psychotic drug, Haloperidol. The patients who mistakenly took Haloperidol suffered acute contractions of the muscles of the face, neck and tongue (dystonia). While it has...

Read more

FDA Takes Action Against Unapproved Prescription Ear Drop Products

Posted 3 weeks ago in Pharma Industry News

July 1, 2015 -- The U.S. Food and Drug Administration today announced its intention to take enforcement action against companies that manufacture and/or distribute certain unapproved prescription ear drop products (known as otic products) labeled to relieve ear pain, infection, and inflammation. The unapproved prescription ear drops contain active ingredients such as benzocaine and hydrocortisone, and have not been evaluated by the FDA for safety, effectiveness and quality. The labels on...

Read more

Monthly News Roundup - June 2015

Posted 4 weeks ago in Pharma Industry News

FDA Approves Antiplatelet Agent Kengreal The U.S. Food and Drug Administration has approved The Medicines Company’s Kengreal (cangrelor), an intravenous blood thinner (P2Y12 platelet inhibitor) used in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of thrombotic events, like heart attack or stent thrombosis, during the procedure. PCI is more commonly known as a coronary (heart) angioplasty. In a clinical trial that compared Kengreal to Plavix (clopidogrel),...

Read more

FDA Panel to Discuss Safety of Contraceptive Device Essure

Posted 4 weeks ago in Pharma Industry News

The U.S. Food and Drug Administration on Wednesday announced that it would hold a public meeting to discuss the safety of the contraceptive device Essure. Essure -- a small metal coil placed via catheter into the fallopian tubes -- is the only permanent birth control device approved for use in the United States. The device received approval in 2002, but over the years the FDA has been alerted to thousands of complaints from women who use the device. Those complaints include abdominal pain,...

Read more

FDA approves brain implant to help reduce Parkinson’s disease and essential tremor symptoms

Posted 6 weeks ago in Pharma Industry News

June 12, 2015 -- The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when medication alone may not provide adequate relief from symptoms such as walking difficulties, balance problems, and tremors. An estimated...

Read more

Genetic Characteristics of Brain Tumors Key to Treatment: Studies

Posted 6 weeks ago in Pharma Industry News

Treatment of brain tumors can be improved by first determining their genetic features, rather than the current standard practice of analyzing tissue samples under a microscope, according to two new studies. Experts say the findings published Wednesday in the New England Journal of Medicine are an important advance in what's called precision medicine, in which cancer treatments are individualized according to the genetic characteristics of patients' tumors, The New York Times reported. This...

Read more

FDA Approves First Pediatric Lopinavir/Ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children

Posted 7 weeks ago in Pharma Industry News

Mumbai, India - June 3, 2015 --Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has received US FDA approval for an innovative formulation - Lopinavir/ritonavir (LPV/r) 40mg/10 mg oral pellets - for pediatric specific treatment for infants. Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to...

Read more

Monthly News Roundup - May 2015

Posted 8 weeks ago in Pharma Industry News

Viberzi and Xifaxan FDA-Approved For Diarrhea-Predominant IBS Irritable bowel syndrome with diarrhea (IBS-D) may affect up to 15 million Americans, especially women, and treatment options are limited. In response, the U.S. Food and Drug Administration (FDA) has approved Actavis’ Viberzi (eluxadoline) as a twice-daily, oral treatment for adults suffering from IBS-D. Viberzi has mixed opioid receptor activity. In addition, Salix’s Xifaxan, an antibacterial derived from rifampin, is given...

Read more

FDA Approves Two Therapies to Treat Irritable Bowel Syndrome with Diarrhea (IBS-D)

Posted 8 weeks ago in Pharma Industry News

May 27, 2015 -- The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. According to the National Institutes of Health, patients with irritable bowel syndrome (IBS) experience a number of signs and symptoms, including pain or discomfort in the abdomen and changes in bowel movement patterns. Studies estimate that...

Read more

Monthly News Roundup - April 2015

Posted 12 weeks ago in Pharma Industry News

FDA Approves First-Time Generic for BMS’s Abilify Abilify (aripiprazole) is a blockbuster atypical antipsychotic drug used to treat the mental illnesses schizophrenia and bipolar disorder. On April 28th, the U.S. Food and Drug Administration (FDA) okayed the first generic versions of Abilify, which will save millions of dollars for patients and healthcare systems. Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals and Torrent Pharmaceuticals have received the FDA approval to market...

Read more

FDA Issues Proposed Rule to Address Data Gaps for Certain Active Ingredients in Health Care Antiseptics

Posted 12 weeks ago in Pharma Industry News

April 30, 2015 -- The U.S. Food and Drug Administration today issued a proposed rule requesting additional scientific data to support the safety and effectiveness of certain active ingredients used in health care antiseptics marketed under the over-the-counter drug monograph. “Health care antiseptics are an important component of infection control strategies in hospitals, clinics and other health care settings, and remain a standard of care to prevent illness and the spread of...

Read more

FDA Approves First Generic Abilify (aripiprazole) to Treat Mental Illnesses

Posted 13 weeks ago in Pharma Industry News

April 28, 2015 -- The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms. “Having access to treatments is important for patients...

Read more

Ferring Pharmaceuticals Receives FDA Approval for Growth Hormone Name Change, Acquires Zomacton [somatropin (rDNA origin)]

Posted 16 weeks ago in Pharma Industry News

PARSIPPANY, N.J., March 31, 2015 – Ferring Pharmaceuticals Inc. today announced U.S. Food and Drug Administration (FDA) approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as Zomacton [somatropin (rDNA origin)] for injection, and its needle-free delivery system to be marketed in the U.S. as ZOMA-Jet™. Ferring purchased the U.S. rights to Zomacton, formerly TEV-TROPIN®, and to ZOMA-Jet™, formerly Tjet®, in December 2014 from...

Read more

FDA Issues Final Guidance on the Evaluation and Labeling of Abuse-Deterrent Opioids

Posted 16 weeks ago in Pharma Industry News

April 1, 2015 -- The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties. Opioid drugs provide significant benefit for patients when used properly; however opioids also carry a risk of misuse, abuse and death. To combat opioid misuse and abuse, the FDA is encouraging manufacturers to develop abuse-deterrent drugs that work correctly when taken as prescribed, but, for example, may be...

Read more

Monthly News Roundup - March 2015

Posted 17 weeks ago in Pharma Industry News

FDA Approves First Biosimilar Product Zarxio On Friday, March 6th the U.S. Food and Drug Administration (FDA) approved Sandoz’s Zarxio (filgrastim-sndz), the first U.S. approved biosimilar. Zarxio, the biosimilar for Amgen’s filgrastim (Neupogen), is a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments. Biological products are generally derived from a living organism, including humans, animals, microorganisms or yeast. According to...

Read more

Federal Judge Enters Consent Decree Against Specialty Compounding LLC

Posted 19 weeks ago in Pharma Industry News

March 11, 2015 -- U.S. District Judge Lee Yeakel entered a consent decree of permanent injunction on March 10, 2015 between the United States and Specialty Compounding LLC, of Cedar Park, Texas, and the company’s co-owners, Raymond L. Solano, III and William L. Swail. According to the complaint filed with the consent decree, Specialty Compounding manufactured purportedly sterile injectable drug products that tested positive for bacterial contamination. The U.S. Department of Justice brought...

Read more

Monthly News Roundup - February 2015

Posted 21 weeks ago in Pharma Industry News

Sanofi Receives FDA Approval for Basal Insulin Toujeo The U.S. Food and Drug Administration has approved Sanofi’s Toujeo (insulin glargine [rDNA origin], a once-daily long-acting basal insulin for adults with type 1 or type 2 diabetes. In the clinical trials evaluating Toujeo, all of the primary study endpoints were met by demonstrating similar blood sugar control with Toujeo as compared to Lantus. The most common adverse events (excluding hypoglycemia) reported for Toujeo included...

Read more

Lupin Receives FDA Approval for Generic Lumigan Ophthalmic Solution 0.03%

Posted 22 weeks ago in Pharma Industry News

Mumbai, India and Baltimore, Maryland -- February 23, 2015: Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Bimatoprost Ophthalmic Solution, 0.03% from the United States Food and Drugs Administration (FDA) to market a generic version of Allergan Inc.'s Lumigan Ophthalmic Solution, 0.03%. Lupin Pharmaceuticals Inc. (LPI), the company's U.S. subsidiary would commence marketing the product shortly. Lupin's Bimatoprost Ophthalmic Solution, 0.03% is...

Read more

FDA Approves VenaSeal Closure System to Permanently Treat Varicose Veins

Posted 22 weeks ago in Pharma Industry News

February 20, 2015 -- The U.S. Food and Drug Administration today approved the VenaSeal closure system (VenaSeal system) to permanently treat varicose veins of the legs by sealing the affected superficial veins using an adhesive agent. There are two types of veins—deep veins and superficial veins. Superficial veins are those that are close to the skin. Veins contain one-way valves that open to let blood flow through and then shut to keep blood from flowing backward. When valves of the...

Read more

FDA permits marketing of first direct-to-consumer genetic carrier test for Bloom syndrome

Posted 22 weeks ago in Pharma Industry News

The U.S. Food and Drug Administration today authorized for marketing 23andMe’s Bloom Syndrome carrier test, a direct-to-consumer (DTC) genetic test to determine whether a healthy person has a variant in a gene that could lead to their offspring inheriting the serious disorder. Along with this authorization, the FDA is also classifying carrier screening tests as class II. In addition, the FDA intends to exempt these devices from FDA premarket review. The agency plans to issue a notice that...

Read more
Older articles
Hide